Allogeneic CAR T-cell therapy safe, clinically active in metastatic colorectal cancer

An allogeneic chimeric antigen T-cell therapy showed evidence of clinical activity among patients with metastatic colorectal cancer, according to results of a dose-escalation study presented at Gastrointestinal Cancers Symposium.No patients treated so far in the trial have experienced a serious adverse event or developed graft-versus-host disease, according to the study investigators.CYAD-101 (Celyad) is an investigational, non-gene edited allogeneic CAR T-cell therapy that targets the natural killer group 2D ligand (NKG2DL). The CAR co-expresses a T-cell receptor (TCR) inhibitory peptide,Read More

Share on facebook
Share on twitter
Share on linkedin